A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This is a first-in-human evaluation of CT-388 in a double blind, placebo controlled,
randomized, SAD/MAD/MD, safety, tolerance, PK, and PD study when administered as a SC
injection in otherwise healthy overweight and obese adult participants and obese participants
with T2DM.